UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 14, 2005
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Washington
|
|
0-23930
|
|
91-1549568 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1100 Olive Way, Suite 100, Seattle, Washington
|
|
98101 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code (206) 623-7612
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On
November 14, 2005, Targeted Genetics and its collaboration
partner, the International AIDS
Vaccine Initiative, announced that the start of a Phase II clinical trial in South Africa to test
Targeted Genetics’ HIV Vaccine Candidate. A copy of Targeted Genetics’ press release announcing
the initiation of the clinical trial is attached as Exhibit 99.1 to this current report and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
99.1 Press Release Dated November 14, 2005
2